drug
amlodipine besylate
Marketedupdated 3mo agoby China Resources Saike Pharmaceutical Co Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval36 co-mentions · 15 sources
- drugamlodipine27 co-mentions · 16 sources
- drugOLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE27 co-mentions · 16 sources
- drugNorvasc25 co-mentions · 16 sources
- drugAMLODIPINE BESYLATE AND VALSARTAN25 co-mentions · 16 sources
- tagSmall Molecule18 co-mentions · 15 sources
- drugDiovan6 co-mentions · 3 sources
- drugvalsartan6 co-mentions · 3 sources
indications
investigational
Hypertension
all catalysts(5)
approval · 5
Mar 30, 2015
approval
AMLODIPINE BESYLATE AND VALSARTAN (AMLODIPINE BESYLATE) — FDA approval
amlodipine besylate
→
Oct 6, 2025
approval
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE (AMLODIPINE BESYLATE) — FDA approval
amlodipine besylate
→
Oct 15, 2025
approval
AMLODIPINE BESYLATE AND VALSARTAN (AMLODIPINE BESYLATE) — FDA approval
amlodipine besylate
→
Oct 15, 2025
approval
AMLODIPINE BESYLATE AND VALSARTAN (AMLODIPINE BESYLATE) — FDA approval
amlodipine besylate
→
Nov 24, 2025
approval
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE (AMLODIPINE BESYLATE) — FDA approval
amlodipine besylate
→
Trials studying amlodipine besylate
- —Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
- phase4China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
- phase4China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
- phase1Amlodipine 10 mg Tablets Under Fed Conditions
- phase1Amlodipine 10 mg Tablets Under Fasting Conditions
- phase3An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 5, 2029
~3.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Feb 24, 2041formulationUS 11253474
- Feb 24, 2041formulationUS 11458095
- Feb 24, 2041formulationUS 11723866
- Feb 24, 2041formulationUS 12005141
- Feb 24, 2041formulationUS 12226528
- Feb 24, 2041formulationUS 12440441
- Jun 14, 2038formulationUS 10350171
- Jun 14, 2038formulationUS 10350171
- Jun 14, 2038formulationUS 10350171
- Oct 5, 2029compositionUS 78469613.1y
- Oct 5, 2029compositionUS 78469613.1y
- Oct 5, 2029compositionUS 78469613.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that